SBIR-STTR Award

Identification of tumoricidal compounds in Salmonella
Award last edited on: 4/28/03

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Chang-Hung Chen

Company Information

Vion Pharmaceuticals Inc (AKA: OncoRx Inc~MelaRx Pharmaceuticals)

4 Science Park
New Haven, CT 06511
   (203) 498-4210
   info@vionpharm.com
   www.vionpharm.com
Location: Multiple
Congr. District: 03
County: New Haven

Phase I

Contract Number: 1R43CA096292-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2003
Phase I Amount
$100,000
Attenuated Salmonella typhimurium accumulated and multiplied preferentially in tumors as compared to in normal tissues after being injected intravenously into tumor-bearing mice and rats. VNP20009, an attenuated strain with msbB-purl- deletions, is being evaluated in Phase I trials in cancer patients. VNP20009 induced significant tumor growth inhibition in addition to accumulated to high levels in tumors. Some of the closely related strains, however, did not inhibit tumor growth although they accumulated to similar levels, as did VNP20009. The main goal for this proposal is to evaluate differential protein expression in two pairs of bacteria and to identify components that cause tumor growth inhibition by combining the proteomic and genomic approach.

Thesaurus Terms:
Salmonella typhimurium, antineoplastic, biotherapeutic agent, drug discovery /isolation, protein quantitation /detection, protein structure function attenuated microorganism, posttranslational modification, protein localization protein purification, proteomics, two dimensional gel electrophoresis

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----